170 related articles for article (PubMed ID: 10942395)
1. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
Gaiger A; Reese V; Disis ML; Cheever MA
Blood; 2000 Aug; 96(4):1480-9. PubMed ID: 10942395
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.
Tsuboi A; Oka Y; Ogawa H; Elisseeva OA; Li H; Kawasaki K; Aozasa K; Kishimoto T; Udaka K; Sugiyama H
J Clin Immunol; 2000 May; 20(3):195-202. PubMed ID: 10941827
[TBL] [Abstract][Full Text] [Related]
4. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
5. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
[TBL] [Abstract][Full Text] [Related]
6. WT1-specific serum antibodies in patients with leukemia.
Gaiger A; Carter L; Greinix H; Carter D; McNeill PD; Houghton RL; Cornellison CD; Vedvick TS; Skeiky YA; Cheever MA
Clin Cancer Res; 2001 Mar; 7(3 Suppl):761s-765s. PubMed ID: 11300470
[TBL] [Abstract][Full Text] [Related]
7. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
[TBL] [Abstract][Full Text] [Related]
8. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
9. WT1 as a novel target antigen for cancer immunotherapy.
Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
[TBL] [Abstract][Full Text] [Related]
10. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.
King-Underwood L; Pritchard-Jones K
Blood; 1998 Apr; 91(8):2961-8. PubMed ID: 9531607
[TBL] [Abstract][Full Text] [Related]
12. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.
Sundarasetty BS; Singh VK; Salguero G; Geffers R; Rickmann M; Macke L; Borchers S; Figueiredo C; Schambach A; Gullberg U; Provasi E; Bonini C; Ganser A; Woelfel T; Stripecke R
Hum Gene Ther; 2013 Feb; 24(2):220-37. PubMed ID: 23311414
[TBL] [Abstract][Full Text] [Related]
14. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
[TBL] [Abstract][Full Text] [Related]
15. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
16. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
17. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.
Minagawa H; Hashii Y; Nakajima H; Fujiki F; Morimoto S; Nakata J; Shirakawa T; Katayama T; Tsuboi A; Ozono K
BMC Cancer; 2023 Feb; 23(1):167. PubMed ID: 36803483
[TBL] [Abstract][Full Text] [Related]
19. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.
Siehl JM; Thiel E; Heufelder K; Snarski E; Schwartz S; Mailänder V; Keilholz U
Br J Haematol; 2003 Oct; 123(2):235-42. PubMed ID: 14531904
[TBL] [Abstract][Full Text] [Related]
20. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
